The price of Cara Therapeutics Inc (NASDAQ: CARA) closed at $0.83 in the last session, down -5.60% from day before closing price of $0.87. In other words, the price has decreased by -$0.0490 from its previous closing price. On the day, 578789 shares were traded.
Ratios:
We take a closer look at CARA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.43 and its Current Ratio is at 4.54. In the meantime, Its Debt-to-Equity ratio is 0.76 whereas as Long-Term Debt/Eq ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 08, 2023, Downgraded its rating to Underperform and sets its target price to $6 from $13 previously.
On March 08, 2022, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $17 to $20.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 29 ’24 when Posner Christopher sold 5,834 shares for $0.89 per share. The transaction valued at 5,192 led to the insider holds 180,521 shares of the business.
Goncalves Joana sold 3,293 shares of CARA for $2,931 on Feb 29 ’24. The CHIEF MEDICAL OFFICER now owns 56,118 shares after completing the transaction at $0.89 per share. On Feb 29 ’24, another insider, Terrillion Scott, who serves as the SEC’Y; CHIEF COMPLIANCE & G.C. of the company, sold 3,293 shares for $0.89 each. As a result, the insider received 2,931 and left with 91,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARA now has a Market Capitalization of 45.42M and an Enterprise Value of -49.25M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.15 while its Price-to-Book (P/B) ratio in mrq is 0.79. Its current Enterprise Value per Revenue stands at -2.35 whereas that against EBITDA is 0.42.
Stock Price History:
Over the past 52 weeks, CARA has reached a high of $4.75, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is 0.7792, while the 200-Day Moving Average is calculated to be 1.5413.
Shares Statistics:
According to the various share statistics, CARA traded on average about 699.17K shares per day over the past 3-months and 481.1k shares per day over the past 10 days. A total of 54.48M shares are outstanding, with a floating share count of 46.43M. Insiders hold about 15.06% of the company’s shares, while institutions hold 46.63% stake in the company. Shares short for CARA as of Mar 15, 2024 were 2.48M with a Short Ratio of 3.55, compared to 2.23M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.54% and a Short% of Float of 6.33%.
Earnings Estimates
The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.43, while EPS last year was -$0.49. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.23 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$1.1 and -$1.23 for the fiscal current year, implying an average EPS of -$1.15. EPS for the following year is -$1.11, with 4 analysts recommending between -$0.93 and -$1.34.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $1.8M. It ranges from a high estimate of $3.02M to a low estimate of $300k. As of the current estimate, Cara Therapeutics Inc’s year-ago sales were $6.17M, an estimated decrease of -70.80% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $1.78M, a decrease of -74.30% less than the figure of -$70.80% in the same quarter last year. There is a high estimate of $3.54M for the next quarter, whereas the lowest estimate is $300k.
A total of 4 analysts have provided revenue estimates for CARA’s current fiscal year. The highest revenue estimate was $13.66M, while the lowest revenue estimate was $1.3M, resulting in an average revenue estimate of $6.49M. In the same quarter a year ago, actual revenue was $20.97M, down -69.00% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $4.59M in the next fiscal year. The high estimate is $12.55M and the low estimate is $300k. The average revenue growth estimate for next year is down -29.30% from the average revenue estimate for this year.
